Editor’s note

The Modi government’s reforms have tinkered with FDI norms twice, first in November 2015 and more recently in June this year

It is human nature to perceive change as a threat. But turning this threat into an opportunity is a crucial skill

After taking a beating from overseas regulators for the past few years, analysts are finally sounding marginally cautious about…

A national IPR policy, new FDI norms, a possible revamp of the Drugs & Cosmetics Act, Brexit: the pharma sector in India has a…

Dr Reddy's Laboratories' June 11 announcement that it had entered into an agreement with Teva and Allergan to buy eight…

As the Modi Government launches its second anniversary celebration on May 26, the BJP will be organising 200 odd events over a…

Concerned with declining pharma exports in the recent past, the Ministry of Commerce & Industry has tried to burnish the brand…

A notice dated March 30 from the Drug Controller General (India) asking for ‘science-based suggestions/ comments’ on the pros and…

Manufacturing quality has now become probably the single most important concern in the boardrooms of pharmaceutical companies in…

The fixed dose combination (FDC) issue has been a contentious one for years and on March 10 came back to haunt pharma companies in…